Traded as not traded Area served Worldwide Number of employees 7,000 Founded 1950 | Industry Pharmaceuticals | |
 | ||
Formerly called Nordiska Hormon Laboratoriet Key people Frederik Paulsen Jr (Executive Chairman)Michel L. Pettigrew (COO)Pascal Danglas (CMO)Per Falk (CSO) Managing director Marianne Kock (Global Regulatory Affairs, Information, Ipc Copenhagen) SVPs Lars Peter Brunse (Product Supply) Subsidiaries Ferring Pharmaceuticals Poland Sp. z o.o. Profiles | ||
Siemens reference movie ferring pharmaceuticals
Ferring Holding SA, better known as Ferring Pharmaceuticals, is a multinational pharmaceutical company that specializes in the development and marketing of drugs for use in human medicine.
Contents
- Siemens reference movie ferring pharmaceuticals
- More success and joy at work with viwa ferring pharmaceuticals
- History
- Location
- Products
- Corporate governance
- References
More success and joy at work with viwa ferring pharmaceuticals
History
The company was founded by Frederik Paulsen Sr in Malmö, Sweden, in 1950, initially as the Nordiska Hormon Laboratoriet, renamed Ferring in 1954. A ferring in Frisian is a person from the island Föhr off the western coast of Germany. Mr. Paulsen's family originates from that island.
The first major breakthrough was the synthetic production of oxytocin and vasopressin in 1961. With further growth and expansion, the headquarters moved to Copenhagen, Denmark, and subsequently to Switzerland.
In August 2016, the company announced it would acquire the phase III sciatica candidate drug - Condoliase (SI-6603) from Seikagaku for approximately $95 million.
Location
Ferring Holding SA headquarters are located in Saint-Prex, Switzerland. The company holds over 5,000 employees with manufacturing facilities in Europe, South America, China and has built two new facilities in the US and in India.
In Copenhagen, Ferring has a R&D centre in the Ferring Tower in Ørestad. The company has commissioned Foster and Partners to design a new building in the Scanport development which is expected to be completed in 2019. It will have area of 30,000 square metres and have room for 750 employees.
Dutch subsidiary Ferring B.V. expanded to the US in 1980. Ferring established a research group at the Ferring Research Institute in San Diego, CA (USA) in 1996. Ferring assembled a peptide research group that collaborates with academic scientists. The Ferring Research Institute moved to its new home in San Diego in February 2009 with the opening of a 38,000-square-foot facility in Sorrento Valley. The new facility houses expanded research laboratories for peptide medicinal chemistry, biochemistry, bioanalytical, and pharmacology.
In 2012, Ferring Pharmaceuticals funded the Ferring Research Infertility and Gynaecology Grant.
Products
Products are used in reproductive health, gastroenterology, urology, orthopaedics and endocrinology.
Corporate governance
Ferring's chairman is Frederik Paulsen Jr, son of founder Frederik Paulsen Sr. The chief operating officer (COO) of the company is Michel L. Pettigrew. In 2015, Pascal Danglas and Per Falk took the posts of chief medical officer (CMO) and chief science officer (CSO), respectively.